Goldman Sachs Group, Inc. (The) set a €82.00 ($96.47) target price on Sanofi SA (EPA:SAN) in a research note published on Tuesday, October 17th. The brokerage currently has a neutral rating on the stock.
Several other brokerages have also issued reports on SAN. HSBC Holdings plc set a €81.00 ($95.29) price target on Sanofi SA and gave the stock a neutral rating in a report on Wednesday, August 30th. J P Morgan Chase & Co set a €95.00 ($111.76) price objective on Sanofi SA and gave the stock a neutral rating in a research note on Thursday, June 22nd. Jefferies Group LLC set a €87.00 ($102.35) price objective on Sanofi SA and gave the stock a neutral rating in a research note on Thursday, August 24th. Deutsche Bank AG set a €96.00 ($112.94) price objective on Sanofi SA and gave the stock a buy rating in a research note on Tuesday, August 1st. Finally, Kepler Capital Markets set a €89.00 ($104.71) price objective on Sanofi SA and gave the stock a buy rating in a research note on Wednesday, July 26th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company. The stock presently has an average rating of Hold and an average price target of €87.24 ($102.63).
Shares of Sanofi SA (EPA SAN) traded up €0.58 ($0.68) on Tuesday, hitting €79.60 ($93.65). The company had a trading volume of 1,790,000 shares, compared to its average volume of 1,840,000. Sanofi SA has a one year low of €70.94 ($83.46) and a one year high of €92.97 ($109.38).
COPYRIGHT VIOLATION NOTICE: “Sanofi SA (SAN) PT Set at €82.00 by Goldman Sachs Group, Inc. (The)” was first reported by BBNS and is the sole property of of BBNS. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/sanofi-sa-san-pt-set-at-82-00-by-goldman-sachs-group-inc-the/1720614.html.
About Sanofi SA
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with our FREE daily email newsletter.